28A-1060515
PCT、TW I828311
Neurodegenerative diseases include Alzheimer’s disease (AD), Parkinson’s (PD), Huntington’s diseases (HD) and many others. Discovery of sensitive and specific biomarkers for neurodegenerative diseases are essential to facilitate the clinical diagnosis and drug development. Here, we describe a novel focused glycan array technology that potentially can be used as biomarker for disease diagnosis or disease monitoring. The potential application to develop a therapy is possible. The array reported here are focused on gangliosides. By comparing the auto-antibodies against the glycans on the glycan array in normal and patient plasma, we are able to differentiate different neurodegenerative diseases and correlate to the disease progression and clinical diagnosis. This array technology is a novel and sensitive detection system for neurodegenerative diseases.
- Novel array technology for high sensitivity and specificity
- Able to detect specific auto-glycan antibody level in plasma
- Biomarker discovery and diagnosis for neurodegenerative disease patients
- Facilitating drug development
Yun-Ru Chen, Hwai-I Yang, Chiung-Mei Chen, Pei-Ning Wang
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Focused glycan array for diagnosis of neurodegenerative diseases and thereof